Literature DB >> 22231075

Safety profiles come to fore as more drugs approach MS market.

Cormac Sheridan.   

Abstract

Mesh：

Substances：

Year:  2012        PMID： 22231075     DOI： 10.1038/nbt0112-6c

Source DB:  PubMed          Journal:  Nat Biotechnol        ISSN： 1087-0156            Impact factor:   54.908


× No keyword cloud information.
  2 in total

1.  Novartis eyes oral MS drug as potential blockbuster.

Authors:  Mark Ratner
Journal:  Nat Biotechnol       Date:  2010-11       Impact factor: 54.908

2.  IL-7 promotes T(H)1 development and serum IL-7 predicts clinical response to interferon-β in multiple sclerosis.

Authors:  Li-Fen Lee; Robert Axtell; Guang Huan Tu; Kathryn Logronio; Jeanette Dilley; Jessica Yu; Mathias Rickert; Bora Han; Winston Evering; Michael G Walker; Jing Shi; Brigit A de Jong; Joep Killestein; Chris H Polman; Lawrence Steinman; John C Lin
Journal:  Sci Transl Med       Date:  2011-07-27       Impact factor: 17.956
  2 in total
  1 in total

1.  Risk-benefit considerations in the treatment of relapsing-remitting multiple sclerosis.

Authors:  Alessandra Lugaresi; Maria di Ioia; Daniela Travaglini; Erika Pietrolongo; Eugenio Pucci; Marco Onofrj
Journal:  Neuropsychiatr Dis Treat       Date:  2013-06-24       Impact factor: 2.570
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.